PP
NBIX icon

Prudential plc’s Neurocrine Biosciences NBIX Stock Holding History

Prudential plc’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.36M Buy
8,091
+4,055
+100% +$602K 0.01% 450
2026
Q1 		$532K Sell
4,036
-98
-2% -$13K ﹤0.01% 558
2025
Q4 		$586K Buy
4,134
+98
+2% +$14.2K ﹤0.01% 546
2025
Q3 		$567K Hold
4,036
– – ﹤0.01% 578
2025
Q2 		$507K Buy
+4,036
New +$463K ﹤0.01% 629
2024
Q4 		– Sell
-21,119
Closed -$2.43M – 827
2024
Q3 		$2.43M Buy
21,119
+5,586
+36% +$766K 0.01% 372
2024
Q2 		$2.14M Sell
15,533
-2,884
-16% -$396K 0.01% 383
2024
Q1 		$2.54M Sell
18,417
-1,514
-8% -$207K 0.02% 365
2023
Q4 		$2.63M Sell
19,931
-606
-3% -$69.8K 0.03% 358
2023
Q3 		$2.31M Sell
20,537
-209
-1% -$22K 0.03% 344
2023
Q2 		$1.96M Buy
20,746
+10,591
+104% +$1.03M 0.02% 396
2023
Q1 		$1.03M Buy
10,155
+4,257
+72% +$443K 0.01% 544
2022
Q4 		$704K Buy
5,898
+3,628
+160% +$425K 0.01% 666
2022
Q3 		$241K Buy
+2,270
New +$230K ﹤0.01% 769

Other funds holding NBIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Prudential plc's NBIX Position: Q2 2026 in Review

Prudential plc increased its Neurocrine Biosciences (NBIX) stake by 100% in Q2 2026, buying an estimated $602K and bringing the position to 8,091 shares worth $1.36M. The position accounts for 0.01% of the portfolio, ranked #450.

Prudential plc first reported a position in NBIX in Q3 2022 and has held it in 14 quarters since. The position peaked at $2.63M in Q4 2023. 777 funds tracked by Wall St. Rank hold NBIX as of Q2 2026.

  • Prudential plc held 8,091 shares of Neurocrine Biosciences worth $1.36M as of Q2 2026.
  • Prudential plc bought 4,055 Neurocrine Biosciences shares in Q2 2026, an estimated $602K.
  • Neurocrine Biosciences made up 0.01% of Prudential plc's portfolio in Q2 2026, its #450 holding.
  • Prudential plc first reported a position in Neurocrine Biosciences in Q3 2022 and has held it in 14 quarters since.
  • Prudential plc's Neurocrine Biosciences position peaked at $2.63M in Q4 2023.
  • 777 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q2 2026.

Based on Prudential plc's 13F filing for Q2 2026, filed 14 Aug 2026.